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F U N C T I O N A L E V A L U A T I O N OF P E N I L E HEMODYNAMICS 
C H R I S T I A N G . S T I E F , * W O L F G A N G B A H R E N , H E L M U T G A L L A N D W O L F G A N G S C H E R B 
From the Departments of Urology, Radiology, and Neurology and Psychiatry, Bundeswehr-Krankenhaus, Academic Hospital and Department of 
Dermatology, University, Ulm, Germany 
ABSTRACT 
A multidisciplinary study was performed on 200 consecutive patients with erectile dysfunction 
more than 1 year in duration, which included a standardized intracavernous injection of a vasoactive 
substance mixture (15 mg. per ml. papaverine plus 0.5 mg. per ml . phentolamine). T h e multidisci-
plinary findings correlated well with the intracavernous dose needed for full erection. T h e group 
without pathological hemodynamic findings (36 patients) needed an average of 0.67 ml. and the 
group with pathological inflow (107) needed an average of 1.07 ml . I n the venous insufficiency group 
(57 patients) only 18 achieved full erections with an average of 2.1 ml . (39 achieved tumescence 
only to 3 ml.) . T h e results show that standardized intracavernous injection of a vasoactive substance 
mixture is a useful method to evaluate penile hemodynamics. T h i s pharmacological test appears to 
be effective in the differential diagnosis of nonvascular and vascular erectile dysfunction. ( J . Urol, 
139: 734-737, 1988) 
Owing to the complex nature of erection and the often 
multifactorial genesis of erectile dysfunction, the diagnosis of 
erectile disturbances requires a comprehensive testing pro-
gram. 1 " 5 Only by multidisciplinary collaboration can the spe-
cialization and expertise of the individual physician be 
achieved, which are needed to perform extensive examinations. 
Most of the current therapeutic possibilities of organic erectile 
dysfunction aim at influencing penile hemodynamics. 6" 8 There-
fore, the differentiation among arterial, venous and nonvascular 
causes has a decisive role w i t h respect to therapy. Lue and 
associates demonstrated that the hemodynamic changes i n -
duced by intracavernous injection of vasoactive drugs are iden-
tical to those observed after direct neurogenic stimulation: for 
example papaverine leads to an increase in arterial inflow, a 
relaxation of the cavernous sinus and venous constriction or 
compression.9 
We examine a possible correlation between the multidisci-
plinary findings in our patients w i t h erectile dysfunction and 
the response to standardized intracavernous pharmacological 
testing. 
P A T I E N T S A N D M E T H O D 
We evaluated 200 consecutive patients between 19 and 65 
years old (mean age 45.6 years) who had suffered from erectile 
dysfunction for at least 1 year w i t h respect to the disturbance 
via a multidisciplinary approach. I n anamnesis 28 patients had 
a primary (congenital) erectile dysfunction and 19 had had 
insulin-dependent diabetes for more than 5 years, while 15 
suffered erectile dysfunction after pelvic trauma, 6 after radical 
prostatectomy, 4 after surgery on the large abdominal and 
pelvic vessels, 2 after abdominoperineal proctectomy and 2 
after radiotherapy of the pelvis. Three patients had multiple 
sclerosis and 6 had undergone a revascularization procedure 
without permanent success (see table). 
The detailed history of the patients was taken via question-
naire. Apart from inquiries about the social environment as 
well as the sex life and behavior of the patient and his female 
partner, great importance was attributed to risk factors, the 
situation-related erection process and l i b i d o . 1 0 1 1 Moreover, the 
patients underwent physical examination, laboratory tests ( in -
cluding testosterone and prolactin), nocturnal penile tumes-
Accepted for publication August 12, 1987. 
* Current address: Department of Urology, U518, University of Cal-
ifornia School of Medicine, San Francisco, California 94143. 
cence measurements by means of a Snap-Gauget (showing 
adequate correlation w i t h the sleep laboratory for screening 
purposes), 1 2 bulbocavernosus reflex latency and, i f necessary, 
somatosensory evoked potentials, upper abdominal and pelvic 
sonography, Doppler ultrasonography of the 4 penile arteries 
(proximal and distal), 2 sexual history and psychometry ( M i n -
nesota Multiphasic Personality Inventory and Freiburger Per-
sonality Inventory). Selective pharmacoangiography of the 
pelvis and penis was performed in 59 patients 4 and dynamic 
cavernosography 1 3 , 1 4 was done in 69. The correlation between 
the result of Doppler ultrasonography and angiography was 
94.5 per cent. 1 5 Dynamic cavernosography as an invasive diag-
nostic method requires strict indications, such as insufficient 
rigidity to maximum dosage of intracavernous drugs or only 
ful l r igidity to high doses together w i t h intact penile arterial i -
z a t i o n . 1 6 1 7 
After the patient was appropriately informed, the first 55 
patients received a 1 ml . intracavernous injection. The follow-
ing patients received 0.5 ml . to reduce the high rate of prolonged 
erections (8 of 55 patients: 4 w i t h a neurogenic, 1 a psychogenic 
and 3 an arterial etiology) w i t h 1 ml . of a standardized vaso-
active substance mixture (15 mg. /ml . papaverine hydrochloride 
plus 0.5 mg. /ml . phentolamine methane sulfonate). The injec-
t ion was performed via a 26 gauge half-inch needle into the 
dorsum of the extended penis at about 1 cm. from the abdominal 
wall and 2 to 3 mm. laterally from the midline. I n a control 
group of 10 men w i t h normal potency 0.5 ml . induced a complete 
erection at least 30 minutes i n duration. Under dose variation 
an erection duration of 30 to 90 minutes was to be achieved in 
t Dacomed, Minneapolis, Minnesota. 
Underlying diseases in 200 consecutive patients with erectile 
dysfunction 
No. 
Primary erectile dysfunction 28 
Insulin-dependent diabetes 19 
Post-traumatic 15 
Radical prostatectomy 6 
Cystoprostatectomy 1 
Large abdominal and pelvic vessel surgery 4 
Abdominoperineal proctectomy 2 
Radiotherapy of the pelvis 2 
Multiple sclerosis 3 
Failed penile revascularization 6 
No underlying disease 114 
734 
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the patients and the maximum dose was set at 3 ml . A t least 3 
injections (1 injection per day) per patient were performed at 
the hospital without psychogenic or reflexogenic stimulation. 
The interval u n t i l maximum onset of action as well as quality 
and duration of maximum response were recorded by the urol ­
ogist. The penile reaction was divided into 6 degrees according 
to the palpatory findings: 0—no reaction, 1—slight tumescence, 
2—medium tumescence, 3—complete tumescence w i t h no r i ­
gidity, 4—complete tumescence w i t h medium rigidity and 5— 
complete rigidity. 
Severe hypoplasia or aplasia of both penile arteries on an­
giography and/or Doppler ultrasound was considered an arte­
r ial etiology. A bulbocavernosus reflex latency exceeding 42 
msec, was regarded as a neurogenic etiology. On dynamic 
cavernosography, a maintenance flow greater than 80 ml . per 
minute was considered a venous etiology. 
RESULTS 
During the diagnostic use of vasoactive substances in the 200 
patients studied 19 experienced 21 prolonged erections (dura­
t ion of more than 6 hours). The first 4 erections were treated 
successfully by aspiration of blood from both corpora cavernosa, 
while the remainder were treated by intracavernous injection 
of 2 mg. of the ^-adrenergic stimulator metaraminol. 
According to the results of the multidisciplinary evaluation, 
the etiology was purely arterial in 58 patients, arterio-neuro-
genic in 42, arteriovenous plus neurogenic in 11, arteriovenous 
in 19, arterio-psychogenic in 7, neurogenic in 27, venous in 24, 
psychogenic in 9 and neurogenic-venous in 3. The doses re­
quired by the individual patients to achieve a complete erection 
at least 30 minutes in duration are shown in figure 1. 
I f one arranges these groups under hemodynamic aspects, 
basically different reactions to the intracavernous injection can 
be classified as 1—no effect on hemodynamics, 36 patients (fig. 
1, / and h)y 2—disturbance of arterial inflow w i t h venous 
competence, 107 patients (fig. 1, a, b and e) and 3—excessive 
outflow, 57 patients (fig. 1, c, d, g and i). Mean patient age in 
these 3 groups was 44.7, 46.9 and 45.3 years, respectively. The 
age distribution curves showed no significant differences. I n 
contrast to the normal subjects, 20 of 36 patients without 
pathological hemodynamic findings achieved a complete erec­
t ion after administration of 0.5 ml . or less wi th in 5 to 8 minutes. 
I n this group a mean dose of 0.67 ml . was needed to achieve a 
complete erection (fig. 2, a). A l l patients w i t h arterial insuffi­
ciency achieved a complete erection by means of vasoactive 
substances. The response time was markedly prolonged (up to 
40 minutes) and the mean dose was 1.07 ml . (fig. 2, b). Only in 
18 of 57 patients wi th venous insufficiency (maintenance flow 
more than 100 ml . per minute) could a complete erection be 
achieved by intracavernous injection of vasoactive substances 
and the mean dose was 2.1 ml . in these patients (fig. 2, c). 
D I S C U S S I O N 
Intracavernous injection of a papaverine-phentolamine mix­
ture induces an erection w i t h complete rigidity provided the 
penile hemodynamics are intact and the dosage is adequate.9 
This effect is achieved mainly by relaxation of the smooth 
muscles of the cavernous sinus. Juenemann and associates 
demonstrated the importance of a decrease in penile outflow to 
achieve complete rigidity as a result of this cavernous relaxa­
t i o n . 1 8 Patients in whom the erectile dysfunction is not of 
arterial or venous etiology have a complete erection in response 
to a standardized intracavernous injection of vasoactive sub­
stances. Arterial insufficiency produces prolongation in the 
response time from a normal of 5 to 8 minutes up to 40 minutes 
and, depending upon the extent of the inflow disturbance, an 
increase in dosage is required to achieve complete rigidity. A 
mi ld inflow disturbance cannot be differentiated from an intact 
penile blood supply by means of this test. I f complete rigidity 
cannot be achieved even by maximum doses (45 mg. papaverine 
and 1.5 mg. phentolamine) marked insufficiency of the smooth 
cavernous muscles or abnormal venous channels must be as­
sumed based on the results of animal experiments. 1 6 The i n ­
sufficient reduction in venous outflow prevents the intracav­
ernous pressures that are necessary to achieve complete rigidity 
and i t can be demonstrated as venous leakage by means of 
dynamic cavernosography. This cavernous reaction to intracav­
ernous injection of vasoactive substances can be modulated by 
external and psychological factors, respectively, in terms of an 
increase adrenergic tone but i t can be inhibited completely only 
in rare cases. This penile response to certain intracavernous 
doses of vasoactive substances is well reproducible in the same 
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FlG. 2. Distribution of erectile dysfunction in patients according to 
penile hemodynamic status and dosages required for full erection, a, 
intact penile hemodynamics. 6, pathological inflow, venous competence, 
c, venous leakage. 
individual and some patients reported that in certain stress 
situations " i t didn't function as well as usual". Therefore, the 
dose testing to achieve a 30-minute erection was repeated at 
least twice. 
Virag and associates studied the diagnostic possibilities of 
intracavernous papaverine injection. 1 9 They divided their 45 
patients examined by a multidisciplinary approach into a con­
tro l group, as well as nonorganic and organic erectile dysfunc­
t ion groups. They observed identical reactions in the control 
and the nonorganic (psychogenic) groups. The organic group 
achieved no complete rigidity after an identical papaverine 
injection following a prolonged response time. These results as 
well as those by Nadig, 2 0 and Jünemann 2 1 and S id i 2 2 and their 
associates are compatible w i t h our results. Buvat and 
associates23 performed the papaverine test (80 mg.) recom-
mended by Virag and associates1 9 following dynamic caverno-
sography. No significant difference could be found between 
patients w i th marked pathological arterialization and psycho-
logical origin without organic causes. These results, which 
contradict the findings of the other investigators, could possibly 
be attributed to the increased adrenergic tone following the 
invasive dynamic cavernosography and the 2 needles st i l l pres-
ent in the penis. This assumption is supported by our experi-
ence. I n the course of dynamic cavernosography vasoactive 
substances were injected intracavernously in more than 40 
patients at a dose that was 4 times as high as that normally 
required for complete erection and i t induced a complete erec-
t ion in 7 patients only under these circumstances. 
C O N C L U S I O N 
Intracavernous injection of vasoactive substances in a stand-
ardized form represents a simple and reliable method to eval-
uate penile hemodynamics. To avoid serious side effects such 
injection should be performed only by physicians experienced 
wi th this technique. By means of this pharmacological test a 
rationalized 3-step program was developed to answer therapy 
relevant questions: 1) baseline examination included history, 
physical examination and laboratory testing, 2) specific non-
invasive examinations included pharmacological testing, Dop-
pler sonography and sexual history plus psychometry, and 
abdominal and pelvic sonography, and 3) specific invasive 
examinations (only in certain indications) included dynamic 
cavernosography, angiography, bulbocavernosus reflex latency 
testing and evaluation of the somatosensory evoked potential. 
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EDITORIAL COMMENTS 
The authors support serial intracavernous injections of vasoactive 
agents in the differential diagnosis of impotence and evaluation of 
penile hemodynamics. The diagnosis of impotence is based on the 
quality of the response, time required to achieve the response and dose 
required to induce a full erection. Men with intact penile vasculature 
responded to vasoactive agents with full, rigid erections. Men with 
vasculogenic impotence (that is venous, arterial or mixed), if they 
respond at all, usually require higher doses of medication to induce this 
response, the onset of which may be delayed. 
Several factors should be considered when vasoactive agents are used 
intracavernously in the differential diagnosis of and screening for 
impotence. The same dose administered to the same patient at different 
times may induce a different response. The response may differ if the 
patient is in the supine, standing or sitting position during injection, if 
he is anxious or if there is sexual stimulation. Patients with penile 
arterial insufficiency may have a normal response. An attenuated 
response may occur in up to 44 per cent of the patients with normal 
vasculature despite repeated injection.1 
Vasoactive agents injected intravenously have great potential for the 
differential diagnosis of impotence. However, this potential is not yet 
realized. More test standardization is required so that specificity, 
sensitivity and accuracy can be defined. Factors that should be stand­
ardized include the vasoactive agent used, dose, whether single or 
multiple injections are given, test conditions, use of visual sexual 
stimulation, position during injection and methods to assess the re­
sponse. 
Currently, it appears that a diagnosis of severe venous incompetence 
or severe arterial insufficiency can be excluded with certainty if a full 
erection is achieved after carefully performed intracavernous injection. 
The significance of a partial response or no response still is uncertain. 
A. A. Sidi and Paul H. Lange 
Urology Section 
Veterans Administration Medical Center 
Minneapolis, Minnesota 
1. Buvat, J., Lemaire, Α., Marcolin, G., Dehaene, J. L. and Buvat-
Herbaut, M.: Intracavernous injection of papaverine (ICIP). 
Assessment of its diagnostic and therapeutic value in 100 impo­
tent patients. World J. Urol., 5 : 150, 1987. 
I agree with the authors that intracavernous injection of pharmaco­
logical agents is useful in the evaluation of penile hemodynamics. 
However, owing to the imprecise nature of most of our current diag­
nostic tests to differentiate various types of impotence, the etiological 
classification in this article is oversimplified. A prolonged bulbocaver-
nosus reflex only implies that the patient may have some neurological 
deficit and not necessarily neurogenic impotence. During evaluation of 
the cavernous artery, penile arteriography and Doppler analysis cur­
rently are imprecise and there will be large numbers of false negative 
or positive results in the diagnosis of arteriogenic impotence. 
It must be emphasized that the dosage mentioned by the authors is 
for diagnostic purposes (without sexual stimulation). If the patient is 
to perform self-injection before sexual intercourse the dosage required 
would be much lower. We prefer to start with 0.1 ml. (3 mg.) papaverine 
alone in patients with neurogenic impotence and 0.5 ml. (15 mg.) in 
those with other types, and then we increase the dosage gradually until 
a desirable result is obtained. Use of 2 to 4 mg. metaraminol to treat 
priapism is dangerous. Two deaths have been reported in France owing 
to complications from acute severe hypertension. We prefer a small 
dose of epinephrine (10 M g . / l ml. normal saline) repeated every 5 
minutes after aspiration of 15 to 20 ml. blood. Others prefer irrigation 
with phenylephrine solution. 
Standardization of a dynamic test for erectile dysfunction is a 
difficult task owing to the psychological inhibition that invariably 
occurs in such an artificial environment. I congratulate the authors on 
this endeavor and I stress that when results are equivocal the test 
should be repeated 2 or 3 times to rule out psychological overshadowing 
of organic disease. 
Tom F. Lue 
Department of Urology 
University of California 
San Francisco, California 
REPLY BY AUTHORS 
We appreciate the editorial comments and are in complete agreement 
that, although techniques may be standardized, patients will never be. 
In particular, psychogenic influences may alter the individual response 
to standardized intracavernous pharmacological testing. Accordingly, 
to avoid an attenuated response in an anxious or nervous patient, we 
recommend that pharmacological testing not be performed as the first 
diagnostic procedure for erectile dysfunction. Rather, it should be 
introduced after the urologist has gained the confidence of the patient. 
It should be performed in a secure, quiet environment and it should be 
repeated to prove reproducibility. The complexity of the erectile phe­
nomenon and the current gaps in our knowledge of it currently make 
a precise diagnostic method unavailable. However, we believe that 
standardized intracavernous pharmacological testing, besides minimiz­
ing the use of invasive techniques, provides a useful evaluation of penile 
hemodynamics as an aid to choosing the appropriate therapeutic option. 
